Skip to main content
Equibles
LFST logo

LFST · LifeStance Health Group, Inc.

Track LFST — free

Use LFST with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LFST

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.47 -0.18 (-1.42%) At close · Aug 21
Market Cap
$4.77B
Shares
382.06M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.47 Open$12.65 Day$12.41–12.72 52W close$4.81–12.83 Avg vol 30d3.8M Short int9.6M · 2.5% float · 3.5d Short vol35% Last earningsAug 6, 2026 DataJun 2021–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 15.1 · calm Equity put/call 0.51
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +58%
      above
      Price vs 50-day avg +16%
      above
      RSI (14) 64
      neutral
      MACD trend Positive
      52-week position 96%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +14%
      trailing
      6-month return +75%
      trailing
      YTD return +77%
      this year
      Relative strength +63%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $8 — 50d above 200d
      Institutional flow Accumulating
      +26% holders QoQ · +92 funds added
      Insider flow Distributing
      Net -$151.0M over 90 days · 100% sells
      Short interest Rising
      2.51% of float · ▲ +1.2% MoM · 3.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      288 holders — near 3-yr high, broad support
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +14%
      Y/Y
      Free cash flow $110.0M
      Buyback $100.0M
      authorized
      Balance sheet $31.8M
      net debt
      Quant / Vol
      risk profile
      High
      Volatility 54%
      annualized · 1-yr
      Max drawdown −17%
      past year
      ATR 4.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 5 of last 6
      Latest guidance · from the 8-K filed Aug 6, 2026
      full year 2026
      Center Margin Initiated $570M – $594M
      Adjusted EBITDA Non-GAAP Initiated $215M – $235M
      third quarter of 2026
      Center Margin Initiated $140M – $152M
      Adjusted EBITDA Non-GAAP Initiated $49M – $59M
      Total revenue Initiated $420M – $440M
      prior qtr $435.35M midpoint −1.2% QoQ
      Prior guidance period ended · from the 8-K filed May 7, 2026
      Total revenue · second quarter of 2026 $405M – $425M
      Center Margin · second quarter of 2026 $135M – $147M
      Adjusted EBITDA · second quarter of 2026 $50M – $60M
      Guided vs delivered · last 6 settled
      Total revenue fourth quarter of 2025
      guided $368M – $388M
      $382.2M In line
      Total revenue full year 2025
      guided $1.4B – $1.44B
      $1.42B In line
      Total revenue third quarter of 2025
      guided $345M – $365M
      $363.81M In line
      Revenue full year 2024
      guided $1.19B – $1.24B
      $1.25B Beat +3.0%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +58% Bullish
      Price vs 50-day avg
      +16% Bullish
      RSI (14)
      64 Neutral
      MACD trend
      Positive Bullish
      52-week position
      96% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $11 › 200d $8 — 50d above 200d
      Institutional flow Accumulating
      +26% holders QoQ · +92 funds added
      Insider flow Distributing
      Net -$151.0M over 90 days · 100% sells
      Short interest Rising
      2.51% of float · ▲ +1.2% MoM · 3.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      288 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $5 Now $12 · 96% Range high $13
      vs 200-day avg +58% vs 50-day avg +16%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP Net income (loss) 23.61M
      +2.63M Interest expense, net
      +14.25M Depreciation and amortization
      +3.85M Income tax provision (benefit)
      +26K Loss on remeasurement of contingent consideration
      +19.75M Stock-based compensation expense
      +93K Loss on disposal of assets
      +445K Transaction costs
      +0K Executive transition costs
      +69K Litigation costs
      +911K Strategic initiatives
      -11K Real estate optimization and restructuring charges
      +423K Amortization of cloud-based software implementation costs
      = Adjusted EBITDA 66.04M
      GAAP → non-GAAP reconciliation
      GAAP Income (loss) from operations 30.65M
      +14.25M Depreciation and amortization
      +108.14M General and administrative expenses
      = Center Margin 153.04M
      Center Margin % of total revenue non-GAAP 35.2% Q2 2026 —
      Centers 550 as of June 30, 2026 —
      Clinician Y/Y Growth 11% TTM ending June 30, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net cash provided by (used in) operating activities $99.9M
      -$12M Purchases of property and equipment
      = Free Cash Flow $87.9M
      % Margin non-GAAP 12.7% Q1 —
      Adjusted EBITDA % of revenue non-GAAP 12.7% Q1 2026 —
      Center Margin % of revenue non-GAAP 33.7% Q1 2026 —
      Center Margin (Non-GAAP) non-GAAP $135.9M Q1 —
      Clinicians 8,349 Q1 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      LFST
      LifeStance Health Group, Inc.
      this stock
      		$4.77B +77.1% +13.9% — 2.5%
      HCA
      HCA Healthcare, Inc.
      		 $95.24B -8.1% +7.1% 14.8 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      		 $30.64B -4.8% — — 0.0%
      THC
      Tenet Healthcare Corp
      		 $22.61B +41.3% +0.9% 10.8 4.0%
      FMS
      Fresenius Medical Care AG
      		 $12.49B -1.6% +5.9% — 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      288
      % held
      98.4%
      Net QoQ
      +7.4M sh
      Top holder
      TPG GP A, LLC
      Held Float
      View
      Held by Funds
      Fund positions
      242
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      9.6M
      Days to cover
      3.5d
      Change
      +111.2K sh
      View
      Short Volume
      Short vol %
      35%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      920
      Value
      $10.0K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      37.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$151.0M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $1.4B
      Net income (FY)
      $9.7M
      View
      Buybacks
      Authorized
      $100.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $95.1K
      Shares
      7.5K
      Filed
      Aug 14, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      LFST +0.4% +14.4% +74.7% +19.0% +77.1%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +1.8% +10.8% +63.1% +16.5% +64.8%

      Capital returns

      Buyback program · as of Aug 5, 2026
      Authorized
      $100.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1845257 CUSIP 53228F101 13F (30d) 259 filings 255 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)